IMTX vs. SWTX, IOVA, ACLX, APGE, DNLI, TWST, VCEL, IMCR, ADMA, and RXRX
Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Vericel (VCEL), Immunocore (IMCR), ADMA Biologics (ADMA), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "biological products, except diagnostic" industry.
SpringWorks Therapeutics (NASDAQ:SWTX) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.
SpringWorks Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
64.4% of Immatics shares are held by institutional investors. 7.6% of SpringWorks Therapeutics shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
SpringWorks Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -107.80%. SpringWorks Therapeutics' return on equity of -29.36% beat Immatics' return on equity.
SpringWorks Therapeutics received 65 more outperform votes than Immatics when rated by MarketBeat users. However, 72.22% of users gave Immatics an outperform vote while only 68.42% of users gave SpringWorks Therapeutics an outperform vote.
Immatics has higher revenue and earnings than SpringWorks Therapeutics. Immatics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, SpringWorks Therapeutics had 7 more articles in the media than Immatics. MarketBeat recorded 8 mentions for SpringWorks Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 0.95 beat SpringWorks Therapeutics' score of 0.93 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
SpringWorks Therapeutics presently has a consensus target price of $68.83, indicating a potential upside of 66.02%. Immatics has a consensus target price of $16.00, indicating a potential upside of 45.06%. Given Immatics' higher possible upside, research analysts clearly believe SpringWorks Therapeutics is more favorable than Immatics.
Summary
SpringWorks Therapeutics beats Immatics on 10 of the 17 factors compared between the two stocks.
Get Immatics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immatics Competitors List
Related Companies and Tools
